Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Vivesto AB ( (SE:VIVE) ) is now available.
Vivesto AB has initiated dosing of the first dogs in a pharmacokinetic and toxicology study of its cancer drug candidate Cantrixil, a key step in its hematological cancer development program. The exploratory study in four dogs will assess exposure, tolerability and dosing strategy, with early signs indicating good tolerability and results expected in summer 2026.
Data from this study are intended to support future human trials in acute myeloid leukemia as well as a planned pilot study in dogs with cancer in the second half of 2026. By broadening Cantrixil’s indication to include veterinary oncology and leveraging synergies between its human and animal programs, Vivesto is positioning the asset across both markets while advancing toward a Phase I AML trial and continued CMC work for clinical material.
The most recent analyst rating on (SE:VIVE) stock is a Hold with a SEK0.08 price target. To see the full list of analyst forecasts on Vivesto AB stock, see the SE:VIVE Stock Forecast page.
More about Vivesto AB
Vivesto AB is a Swedish oncology-focused development company aiming to provide new treatments for hard-to-treat cancers with high unmet medical need and significant market potential. Its portfolio includes Cantrixil, being developed for blood cancers, and the veterinary oncology program Paccal Vet, currently evaluated in pilot trials in dogs and dose-finding studies in cats with solid tumors. Vivesto’s shares trade on Nasdaq Stockholm under the ticker VIVE.
Average Trading Volume: 1,580,014
Technical Sentiment Signal: Sell
Current Market Cap: SEK88.9M
Find detailed analytics on VIVE stock on TipRanks’ Stock Analysis page.